UBS Group’s Zivo Bioscience, Inc. Warrants ZIVOW Stock Holding History

UBS Group’s Portfolio ZIVOW Stock Details ZIVOW Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-30	Closed	-$13	–	10404
2023 Q3	$13	Buy	+30	New	+$15	﹤0.01%	9189
2023 Q1	–	Sell	-5,955	Closed	-$417	–	10979
2022 Q4	$417	Buy	5,955 +614	+11%	+$428	﹤0.01%	10194
2022 Q3	$3K	Buy	5,341 +1,741	+48%	+$1.46K	﹤0.01%	9635
2022 Q2	$2K	Buy	3,600 +300	+9%	+$202	﹤0.01%	9688
2022 Q1	$2K	Buy	3,300 +1,873	+131%	+$1.48K	﹤0.01%	9731
2021 Q4	$1K	Buy	1,427 +130	+10%	+$121	﹤0.01%	10096
2021 Q3	$1K	Buy	1,297 +307	+31%	+$350	﹤0.01%	9318
2021 Q2	$1K	Buy	+990	New	+$1.31K	﹤0.01%	9233

UBS Group's ZIVOW Position: Q4 2023 in Review

UBS Group sold out of Zivo Bioscience, Inc. Warrants (ZIVOW) in Q4 2023, closing a stake of 30 shares — an estimated $13 sold.

UBS Group first reported a position in ZIVOW in Q2 2021 and held it in 8 quarters. The position peaked at $3K in Q3 2022. 0 funds tracked by Wall St. Rank hold ZIVOW as of Q4 2023.

UBS Group reported no remaining Zivo Bioscience, Inc. Warrants position as of Q4 2023 after selling out during the quarter.
UBS Group sold 30 Zivo Bioscience, Inc. Warrants shares in Q4 2023, an estimated $13.
UBS Group first reported a position in Zivo Bioscience, Inc. Warrants in Q2 2021 and held it in 8 quarters.
UBS Group's Zivo Bioscience, Inc. Warrants position peaked at $3K in Q3 2022.
0 funds tracked by Wall St. Rank held Zivo Bioscience, Inc. Warrants as of Q4 2023.

Based on UBS Group's 13F filing for Q4 2023, filed 9 Feb 2024.